MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA

Archives of gerontology and geriatrics9 Nov 2010Cited by 48 (Europe PMC)

PMID21067829DOI10.1016/j.archger.2010.10.004PepBankPUB-21067829

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In elderly hip fracture patients, MK-0677 did not significantly improve stair climbing power versus placebo at 24 weeks.
In plain wordsIn elderly hip fracture patients, MK-0677 did not significantly improve stair climbing power compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeStair climbing power
Study
n = 123
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Measurements
Mean stair climbing power difference
12.5 W
MK-0677 versus placebo
P value
0.292
versus placebo
95% confidence interval for mean stair climbing power difference
−10.95 to 35.88 W
MK-0677 versus placebo at 24 weeks
Source sentences
Summary
At 24-weeks, the mean stair climbing power increased by 12.5 W in the MK-0677 group (95% confidence interval (CI) = -10.95-35.88; p = 0.292) compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782901
02HumanRandomized controlled trialEfficacy outcome
In elderly hip fracture patients, MK-0677 improved gait speed compared with placebo.
In plain wordsIn elderly hip fracture patients, MK-0677 improved gait speed compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGait speed
Study
n = 123
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Measurements
Gait speed mean score difference
0.7 score
MK-0677 versus placebo
95% confidence interval for gait speed mean score difference
0.17 to 1.28 score
MK-0677 versus placebo
P value
0.011
gait speed mean score difference: MK-0677 versus placebo
Source sentences
Summary
Gait speed increased by a 0.7-score difference in the means (95% CI = 0.17-1.28; p = 0.011).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782902
03HumanRandomized controlled trialEfficacy outcome
In elderly hip fracture patients, MK-0677 did not improve several other functional performance measures.
In plain wordsIn elderly hip fracture patients, MK-0677 did not improve several other physical performance measures compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeOther functional performance measures
Study
n = 123
Comparator
Placebo
Analysis
Primary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
There was no improvement in MK-0677 treated patients in several other functional performance measures.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782903
04HumanRandomized controlled trialEfficacy outcome
In elderly hip fracture patients, MK-0677 increased IGF-1 by 51.4 ng/ml compared with placebo.
In plain wordsIn elderly hip fracture patients, MK-0677 increased IGF-1 compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseIGF-1 levels
Study
n = 123
Comparator
Placebo
Analysis
Primary
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Measurements
IGF-1 difference
51.4 ng/ml
versus placebo
95% confidence interval for IGF-1 difference
34.42 to 68.44 ng/ml
MK-0677 versus placebo
P value
< 0.001
IGF-1 difference: MK-0677 versus placebo
Source sentences
Summary
Levels of IGF-1 in treated patients increased by 51.4 ng/ml (95% CI = 34.42-68.44; p < 0.001) compared to placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782906
05HumanRandomized controlled trialSafety outcome
In elderly hip fracture patients, the MK-0677 group had fewer falls than placebo. The abstract gives p = 0.096 and does not state significance for this comparison.
In plain wordsIn elderly hip fracture patients, the MK-0677 group had fewer falls than placebo. The abstract does not call this significant (p = 0.096).
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseFalls
Study
n = 123
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
The MK-0677 group experienced fewer falls during the study compared to placebo and smaller number of patients who had any falls (p = 0.096).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782904
06HumanRandomized controlled trialSafety outcome
In elderly hip fracture patients, fewer MK-0677 recipients had any falls than placebo recipients, without statistical significance.
In plain wordsIn elderly hip fracture patients, fewer MK-0677 recipients fell than placebo recipients, but the difference was not statistically significant.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePatients with any falls
Study
n = 123
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
25mg/day · 24 weeksAs given in this study (human).
Measurements
P value
0.096
patients with any falls
Source sentences
Summary
The MK-0677 group experienced fewer falls during the study compared to placebo and smaller number of patients who had any falls (p = 0.096).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782905
07HumanRandomized controlled trialSafety outcome
In elderly hip fracture patients, the MK-0677 trial ended early because of a congestive heart failure safety signal.
In plain wordsIn elderly hip fracture patients, the MK-0677 trial ended early because of a heart failure safety signal.
Peptide
MK-677 (ibutamoren)
Outcome
Direction not reportedCongestive heart failure safety signal
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Studied dose
25mg/dayAs given in this study (human).
Source sentences
Summary
Trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a randomized, double-blind study of 123 elderly hip fracture patients assigned to receive 25mg/day of MK-0677 (n = 62) or placebo (n = 61).
Summary · context
Primary outcomes were a rank analysis of change during the study in objective functional performance measurements and insulin-like growth factor-1 (IGF-1) levels in blood.
Report a problemFND-2106782907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2NCT00128115

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Merck Sharp & Dohme LLCn = 83Sept 2005 to Aug 2007

Hip Fracture

Trial page ClinicalTrials.govUpdated 20 Jan 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.